Omega Fund Management buys $33,935,351 stake in Paratek Pharmaceuticals Inc (PRTK)

Paratek Pharmaceuticals Inc (PRTK) : Omega Fund Management scooped up 461,538 additional shares in Paratek Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 2,600,410 shares of Paratek Pharmaceuticals Inc which is valued at $33,935,351.Paratek Pharmaceuticals Inc makes up approximately 25.10% of Omega Fund Management’s portfolio.

Other Hedge Funds, Including , Swiss National Bank boosted its stake in PRTK in the latest quarter, The investment management firm added 5,500 additional shares and now holds a total of 20,900 shares of Paratek Pharmaceuticals Inc which is valued at $272,745. Fny Managed Accounts added PRTK to its portfolio by purchasing 1,000 company shares during the most recent quarter which is valued at $13,000. Paratek Pharmaceuticals Inc makes up approx 0.01% of Fny Managed Accounts’s portfolio. Bnp Paribas Arbitrage Sa added PRTK to its portfolio by purchasing 563 company shares during the most recent quarter which is valued at $7,482.

Paratek Pharmaceuticals Inc opened for trading at $13.09 and hit $13.235 on the upside on Monday, eventually ending the session at $13.15, with a gain of 1.00% or 0.13 points. The heightened volatility saw the trading volume jump to 1,27,705 shares. Company has a market cap of $298 M.

Many Wall Street Analysts have commented on Paratek Pharmaceuticals Inc. Company shares were Reiterated by H.C. Wainwright on Jun 17, 2016 to “Buy”, Firm has raised the Price Target to $ 34 from a previous price target of $31 .Robert W. Baird Initiated Paratek Pharmaceuticals Inc on May 13, 2016 to “Outperform”, Price Target of the shares are set at $30.

Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *